RxDoctor Payments Data

Ashok Tyagi, DO

Pulmonary Disease · Saint Petersburg, FLNPI 1912113804

Payments from drug & device makers

$2,894in general payments, 2019–2025

Across 27 payments — averaging $107.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Olympus Corporation Of The Americas$2K
  • Abbott$448
  • Inspire Medical Systems, Inc.$72
  • GSK$38
  • Harmony Biosciences LLC$36
  • Actelion Pharmaceuticals US, Inc.$29
  • plus $64 from 3 others

What the payments were for

  • Travel & lodging$2,12773%
  • Food & beverage$76827%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,894 in reported general payments places this provider in the 45th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida

Medicare billing

Part B allowed, 2024
$484,191
Medicare patients
1,150
Services billed
5,168

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter120$92,921
Breztri AerosphereBudesonide/Glycopyr/Formoterol38$24,929
EliquisApixaban25$15,502
SymbicortBudesonide/Formoterol Fumarate49$14,857
Breo ElliptaFluticasone/Vilanterol19$10,837
Spiriva HandihalerTiotropium Bromide17$9,004
Roflumilast34$3,658
Albuterol Sulfate HfaAlbuterol Sulfate94$2,776
Azithromycin75$1,347
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$1,310
Prednisone94$525
Zolpidem Tartrate34$494
Fluticasone Propionate33$352
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav23$236
Doxycycline Hyclate17$196

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$38$103,758139 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 953 pulmonary disease providers in Florida.

Other pulmonary disease in Saint Petersburg

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →